Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Risk Stratification in Metastatic Renal Cell Carcinoma

EP. 1: Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

EP. 2: Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

EP. 3: Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

EP. 4: mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

EP. 5: Evaluating I-O Monotherapy's Value in Treating mRCC

March 29th 2019

EP. 6: Frontline Therapy for mRCC: Sequencing and Goals

March 29th 2019

EP. 7: Selecting an Optimal Second-Line Regimen for mRCC

March 29th 2019

EP. 8: Goals in Previously Treated Advanced Renal Cell Carcinoma

March 29th 2019

EP. 9: Novel Combinations in mRCC: Axi/Pembro vs Axi/Avelumab

March 29th 2019

EP. 10: mRCC: When is TKI/I-O Combination Therapy Appropriate?

March 29th 2019

EP. 11: Further Exploring TKI/I-O Combination Regimens in mRCC

March 29th 2019

EP. 12: Future Directions in Renal Cell Carcinoma Management

March 29th 2019
Advertisement
Advertisement

Trending on OncLive

1

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

2

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

3

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

4

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

5

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us